B - Obesity Medicine Injectables: Considerations and Caveats and Opportunities on the Horizon

Nutrient Stimulated Hormones (NuSHs) is the preferred term for anti-obesity injectable medications. The purpose of this lecture is to review NuSHs currently on the market and their mechanisms, including non-GLP1 medications like Setmelanotide, as well as future treatments options on the horizon. Research from those of Dr. Acosta and his team have shown not every individual will respond equally to GLP1 receptor-agonist medications like Semaglutide or Tirzepatide, and this lecture aims to review that literature. This lecture also aims to review important considerations and caveats when using this class of medication such as drug-drug interactions, use with concurrent co-morbid medical conditions, side-effect mitigation, and considerations when comanaging with other providers. In regard to future treatment options, the lecture aims to discuss GIPR/GLP1R agonists such as Maridebart Cafraglutide (AMG133), GCGR/GLP1R agonist like Survodutide (BI456906), CagriSema, Retatrutide, Pemvidutide, LB54640, Bimaugrimab, etc.